Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2020: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2019: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2018: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
Outline of Final Research Achievements |
In pancreatic ductal adenocarcinoma (PDAC), mesenchymal stem cells-derived tumor stroma seems to promote tumor development. However, involvement of bone marrow (BM)-derived cells on tumor progression and its mechanism remains unclear. We aimed to investigate an association between pancreatic cancer progression and BM-derived cells. In the pancreas of allogeneic models, GFP+BM-derived immune cells were accumulated at invasive front, and a few GFP+aSMA+ cells were detected. Some BM-derived cells interacted with pancreatic cancer cells (PCCs) expressed CAF markers. The heterogeneity of PCCs for PDAC development was investigated using whole exome sequencing. We identified the several organ-specific mutations.
|